All In Biotech

Drug Trial Radar · NCT00092014

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,053

Actual

Start

Sep 1, 2002

Primary completion

Apr 1, 2004

Study completion Apr 1, 2004

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 24, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • AlendronateDrug

    Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

  • Risedronate 35 mgDrug

    Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

  • Elemental CalciumDietary supplement

    Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

  • Vitamin DDietary supplement

    Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

  • Risendronate placeboDrug

    Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

  • Alendronate placeboDrug

    Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change from baseline in hip trochanter bone mineral density (BMD) at 12 monthsTime frame: Baseline and 12 months
  2. Mean percent change from baseline in hip trochanter BMD at 24 monthsTime frame: Baseline and 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.